Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. The Audited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries has informed BSE that its Board of Directors will meet on Friday, 30 May 2025, to consider and approve the audited financial results for the quarter and year ended 31 March 2025. The Board will also consider the Directors' Report, Corporate Governance Report, Management Discussion and Analysis Report, and the notice for the 32nd Annual General Meeting. Other agenda items include appointing M/s Meenu Maheshwari & Associates as Secretarial Auditor for FY26, re-appointing Mr. Arvind Sapkal as Independent Non-Executive Director for another five-year term, and re-appointing the Internal Auditors for FY26. The trading window for designated persons remains closed from 1 April 2025 until 48 hours after the results are announced.
This is a routine advance intimation of a board meeting, not an actual results announcement. Shareholders should watch for the audited FY25 results on 30 May 2025, which will be the key event for assessing the company's full-year financial performance.